Navigation Links
Not taking gastroprotective drugs prescribed with anti-inflammatory medicines
Date:4/15/2012

To relieve pain, arthritis sufferers are prescribed medications that may include non-steroidal anti-inflammatory drugs (NSAIDs) or cyclooxygenase-2 (COX-2) inhibitors, both of which can irritate the digestive tract. At times additional drugs are co-prescribed with NSAIDs or COX-2 inhibitors to prevent adverse gastrointestinal (GI) effects. Now a new study available today in the American College of Rheumatology journal, Arthritis & Rheumatism, reveals that decreasing gastroprotective agent (GPA) adherence among users of COX-2 inhibitors is linked to an increased risk of such upper GI complications.

Current clinical guidelines recommend that GPAs, such as proton pump inhibitors (PPIs) or misoprostol, be prescribed to patients taking NSAIDs and COX-2 inhibitorsalso known as COX-2 blockerswho are at high risk of upper GI events. Previous research shows that in NSAID users who fail to adhere to the GPA regimen, the protective effect of GPA drugs is diminished. However, limited evidence is available regarding the effect of adherence to a gastroprotective drug regimen with COX-2 blocker use, and is the focus of the current investigation led by Dr. Vera Valkhoff with Erasmus University Medical Center in the Netherlands.

Dr. Valkhoff and colleagues analyzed data from population-based primary care registries in the United Kingdom, the Netherlands, and Italy between 1996 and 2008. The study group included 14,416 patients 50 years of age or older who were prescribed COX-2 inhibitors and GPAs. Researchers calculated GPA adherence as the proportion of the COX-2 blocker treatment days covered by a GPA prescription. Cases were part of the COX-2 blocker plus GPA group who had an upper GI complication (GI bleeding or symptomatic ulcer) which included 16,442 episodes.

Researchers noted that of the COX-2 blockers prescribed 43% of participants used celecoxib (Celebrex), 41% rofecoxib (Vioxx),1 and 15% etoricoxib (Arcoxia),2 with most patients using these drugs for less than 30 days. During the study 74 patients had an upper GI event, resulting in an incidence rate of 11.9 per 1,000 COX-2 inhibitor user years. Results showed that the risk of upper GI complication was higher in low GPA adherers (GPA was taken on average one out of five days of COX-2 blocker use, or less) compared to full adherers (GPA was taken four out of five days of COX-2 inhibitor use, or more).

Further analysis found that for every 10% decrease in GPA adherence, there was a 9% increase in the risk of gastrointestinal complications. "Our findings show that with every three day reduction of GPA coverage per 30 days of COX-2 inhibitor use, the risk of upper GI events increases 9%," concludes Dr. Valkhoff. "This study confirms the benefits of GPA adherence in reducing risk of upper GI complications from use of COX-2 blockers." The authors point out that GPA adherence is important in reducing risk of upper GI events with COX-2 blockers, and non-adherence is a modifiable risk factor while conventional risk factors such as a prior GI event or use of anticoagulant therapy are not.


'/>"/>
Contact: Dawn Peters
healthnews@wiley.com
781-388-8408
Wiley-Blackwell
Source:Eurekalert

Related medicine news :

1. Can eradicating a common stomach bug make taking aspirin safer?
2. Gang Murders Taking Toll on Young Males, CDC Says
3. Gang Murders Taking Toll on Young Males: CDC
4. Taking moments to enjoy life helps patients make better health decisions
5. Toddlers Taking HIV Drugs Have Higher Cholesterol
6. More Sore Throats Seen in Acne Patients Taking Antibiotics
7. Male breast cancer patients stop taking tamoxifen early because of drug-related side effects
8. Taking Blood Pressure Meds at Bedtime May Be Better
9. Taking the heat: Asian elephants simply ride out high daytime heat load
10. Patients Taking Antipsychotics Urged to Get Routine Physicals
11. Bad Economic News Taking Toll on Americans Emotions
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/21/2017)... CITY, Utah (PRWEB) , ... April 21, 2017 ... ... of wilderness therapy treatment for adolescents and young adults, has kicked off its ... 20th-Sunday, April 23rd. This year’s theme is “Attachment Informed Therapy for Mental ...
(Date:4/21/2017)... , ... April 21, 2017 , ... The Patient Advocacy ... Health System, with the 2017 Ruth Ravich Patient Advocacy Award in recognition ... advocates. DeVaro was honored with the award at The Beryl Institute’s annual Patient ...
(Date:4/21/2017)... ... ... Alive for Wellness is a group of clinical professionals and ... Alive team uses advanced behavioral sciences treatment modalities to accomplish their goals. ... struggle is based on 10 modalities of treatment that include: , ...
(Date:4/21/2017)... Ramon, CA (PRWEB) , ... April 21, 2017 , ... ... might not understand the estate planning process, or where to even begin. “Now more ... unresolved if you are to properly protect yourself and your family,” said attorney Lisa ...
(Date:4/21/2017)... ... , ... During April 21-23, Super-Sod will join the vendor market of the ... everyone — from the avid gardener to the landscape admirer — during the three-day ... in a grand venue, and we are certainly looking forward to participating in this ...
Breaking Medicine News(10 mins):
(Date:4/19/2017)... , April 19, 2017  Vanderbilt University Medical Center ... in Nashville , Tennesse have been ... Sphincter Stimulation for GERD (LESS GERD) trial. The EndoStim ... long-term reflux control by restoring normal function to the ... million people in the United States ...
(Date:4/19/2017)... 2017  Sorrento Therapeutics, Inc. (NASDAQ: ... developing new treatments for cancer and other unmet ... previously announced underwritten public offering of 23,625,084 shares ... price of $2.00 per share, before deducting underwriting ... by Sorrento.  The net proceeds to Sorrento from ...
(Date:4/19/2017)...  New research provides evidence that an old drug may ... study released today that will be presented at the ... Boston , April 22 to 28, 2017. ... disease, the oral drug levodopa has long been considered the ... the disease progresses, the effects of the medication can partially ...
Breaking Medicine Technology: